Determinants of cardiovascular risk in haemodialysis patients: Post hoc analyses of the AURORA study

American Journal of Nephrology

Volumn 37, Issue 2, 2013, Pages 144-151

  Schneider, Andreas ^a,b   Jardine, Alan G ^a   Schneider, Markus P ^a,g   Holdaas, Hallvard ^c   Holme, Ingar ^d   Fellstroem, Bengt C ^e   Zannad, Faiez ^f   Schmieder, Roland E ^g  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITÉ DE LORRAINE   (France)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cardiovascular events; Epidemiology; Haemodialysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; PHOSPHATE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; POST HOC ANALYSIS; PRIORITY JOURNAL; PULSE PRESSURE; SMOKING; SYSTOLIC BLOOD PRESSURE; UREMIA;

EID: 84873325474     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346710     Document Type: Article

References (33)

1. Yusuf S, Hawken S, Ounpuu S, et al: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
2. Emberson JR, Whincup PH, Morris RW, Walker M: Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 2003; 24: 1719-1726.
3. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
4. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
5. Baxi NS, Jackson JL, Ritter J, Sessums LL: How well do the Framingham risk factors correlate with diagnoses of ischemic heart disease and cerebrovascular disease in a military beneficiary cohort? Mil Med 2011; 176: 408-413.
6. Hawranek M, Gasior M, Gierlotka M, et al: Progression of coronary artery atherosclerosis after acute myocardial infarction: an angiographic study. J Invasive Cardiol 2010; 22: 209-215.
7. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(suppl):S16-S23.
8. Fellstrom BC, Jardine AG, Schmieder RE, et al: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
9. Wanner C, Krane V, Marz W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
10. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002; 80: 99-102.
11. Beddhu S, Kaysen GA, Yan G, et al: Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 721-727.
12. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium . phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
13. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO 4 , Ca . PO 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
14. Drechsler C, Pilz S, Obermayer-Pietsch B, et al: Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31: 2253-2261.
15. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
16. Holdaas H, Holme I, Schmieder RE, et al: Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 2011; 22: 1335-1341.
17. Baigent C, Landray MJ, Reith C, et al: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 2011; 377: 2181-2192.
18. Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362.
19. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
20. Roberts MA, Polkinghorne KR, McDonald SP, Ierino FL: Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. Am J Kidney Dis 2011; 58: 64-72.
21. Kessler M, Zannad F, Lehert P, et al: Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the fosinopril in dialysis study. Nephrol Dial Transplant 2007; 22: 3573-3579.
22. Shuto E, Taketani Y, Tanaka R, et al: Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504-1512.
23. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
24. London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531.
25. Kovesdy CP, Kalantar-Zadeh K: Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 2009; 14: 408-415.
26. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17(suppl 8):29-32, 39-40.
27. Kato A, Takita T, Furuhashi M, Maruyama Y, Hishida A: Comparison of serum albumin, Creactive protein and carotid atherosclerosis as predictors of 10-year mortality in hemodialysis patients. Hemodial Int 2010; 14: 226-232.
28. Snaedal S, Heimburger O, Qureshi AR, et al: Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis 2009; 53: 1024-1033.
29. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002; 17(suppl 11):28-31.
30. De Mutsert R, Grootendorst DC, Axelsson J, Boeschoten EW, Krediet RT, Dekker FW: Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23: 2957-2964.
31. Cano NJ, Fouque D, Roth H, et al: Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18: 2583-2591.
32. Recio-Mayoral A, Banerjee D, Streather C, Kaski JC: Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011; 216: 446-451.
33. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA: IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22: 437-442.